# Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

> **NCT06514027** · PHASE2 · NOT_YET_RECRUITING · sponsor: **BeBetter Med Inc** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** BEBT-109 Capsules
- **DRUG:** Pemetrexed Disodium for Injection
- **DRUG:** Carboplatin Injection
- **DRUG:** Cisplatin Injection

## Key facts

- **NCT ID:** NCT06514027
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2027-06
- **Final completion:** 2027-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514027, "Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06514027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*